The latest price target for CureVac (NASDAQ:CVAC) was reported by JMP Securities on September 16, 2024. The analyst firm set a price target for $16.00 expecting CVAC to rise to within 12 months (a possible 515.38% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for CureVac (NASDAQ:CVAC) was provided by JMP Securities, and CureVac reiterated their market outperform rating.

The last upgrade for CureVac NV happened on January 19, 2023 when UBS raised their price target to $18. UBS previously had a neutral for CureVac NV.

The last downgrade for CureVac NV happened on April 25, 2024 when Leerink Partners changed their price target from $12 to $4 for CureVac NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CureVac, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CureVac was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest CureVac (CVAC) rating was a reiterated with a price target of $16.00 to $16.00. The current price CureVac (CVAC) is trading at is $2.60, which is out of the analyst’s predicted range.